Get started
Author

Chidiamara Maria Njoku

Observed names: C Njoku, Chidiamara M. Njoku, Chidiamara Njoku, Maria Chidiamara Njoku, Sr Chidiamara Njoku
Observed institutions: University of Tasmania, Memorial Sloan Kettering Cancer Center, Duke University, University of California, San Francisco, University of Chicago, RIKEN, Dana-Farber Cancer Institute, James Cook University
ORCID: 0000-0003-3758-2422
Observed ORCID: 0000-0003-3758-2422
OpenAlex ID: A5072207656
Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis
2020 · Jaber S. Alqahtani, Chidiamara M. Njoku, et al. · European Respiratory Review · 149
PDF
Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy
2006 · Cara A. Rabik, Maria Chidiamara Njoku, et al. · Cancer Treatment Reviews · 94
Risk factors and associated outcomes of hospital readmission in COPD: A systematic review
2020 · Chidiamara M. Njoku, Jaber S. Alqahtani, et al. · Respiratory Medicine · 82
Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2012 · Heather E. Wheeler, Eric R. Gamazon, et al. · Clinical Cancer Research · 59
PDF
COPD in Africa: risk factors, hospitalisation, readmission and associated outcomes—a systematic review and meta-analysis
2023 · Chidiamara Maria Njoku, John R Hurst, et al. · Thorax · 13
PDF
Multifaceted Interventions Inclusive of Medication Optimization for Frailty in Aged Care: A Systematic Review
2024 · Chidiamara M. Njoku, Fiona Barnett, et al. · Journal of the American Medical Directors Association · 4
Hospital Readmission Due to Chronic Obstructive Pulmonary Disease: A Longitudinal Study
2022 · Chidiamara Maria Njoku, Barbara Caecilia Wimmer, et al. · International Journal of Health Policy and Management · 4
PDF
The Frailty Reduction via Implementation of Exercise, Nutrition, and Deprescribing (FRIEND) Trial: Study Protocol and Recruitment Results
2024 · Michael Inskip, Carolina Almendrales Rangel, et al. · Methods and Protocols · 3
PDF
Getting long-term oxygen therapy right
2025 · Masooma Aqeel, Karen Czischke, et al. · The Lancet Global Health · 1
Audit of Best Practice Frailty Care Capacity Including Robust Exercise Within Residential Aged Care Facilities in North Queensland
2026 · Michael Inskip, Nathan Dawes, et al. · Journal of Clinical Exercise Physiology
PDF
National Readiness for Best-practice Frailty Care Including Robust Exercise and Accredited Exercise Physiologists in Residential Aged Care Homes
2026 · Michael Inskip, Rebecca Wielandt, et al. · Journal of Clinical Exercise Physiology
Perceptions Towards Integrating Accredited Exercise Physiologists Into Residential Aged Care in North Queensland: Preliminary Findings for Workforce Integration and Development
2026 · Rebecca Wielandt, Anthony Leicht, et al. · Journal of Clinical Exercise Physiology
Frailty Reduction Via Implementation of Exercise, Nutrition and Deprescribing (friend) Trial: Novel Implementation of the Asia-pacific Frailty Guidelines in Aged Care
2024 · Dr Michael Inskip, Dr Trinidad Valenzuela Arteaga, et al. · Journal of Clinical Exercise Physiology
Supplementary Figure 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
PDF
Supplementary Figure Legend from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Supplementary Table 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Supplementary Table 3 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Supplementary Table 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
PDF
Supplementary Figure 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Data from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Data from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Supplementary Table 1 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
PDF
Supplementary Table 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
Supplementary Figure 2 from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
PDF
Supplementary Figure Legend from Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy
2023 · Heather E. Wheeler, Eric R. Gamazon, et al.
PDF
Works count: 29
Citation count: 409
H-index: 5
I10-index: 5
Year
Topic
Type